Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, demonstrated consistent efficacy and safety regardless of diuretic type or dose and reduced overall diuretic requirements in patients ...
Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction ...
LISBON — The diabetes and weight-loss drug semaglutide improves heart failure–related symptoms and physical limitations regardless of diuretic use in patients with obesity-related heart failure and ...
Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction ...
Finerenone reduced heart failure events and cardiovascular deaths in patients with HFmrEF or HFpEF when used with diuretics. The study found finerenone reduced hypokalemia risk but increased ...
End-stage kidney disease (ESKD) is characterized by sodium and fluid retention, a significant determinant of hypertension, congestive heart failure and cardiovascular mortality 1. Among therapeutic ...
Diuretic therapy remains a cornerstone in the management of heart failure, targeting intravascular and interstitial volume overload to alleviate symptoms, improve exercise tolerance and reduce ...
A new analysis suggests that finerenone (Kerendia), a newer heart failure medication, may help older adults rely less on high doses of water pills. The findings come from the large FINEARTS-HF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results